BioSpace News Archive

Pharm Country

Ferring Pharmaceuticals Secures Patient Access to EUFLEXXA ® with Blue Cross Blue Shield of Michigan

Medicare Advantage and Commercial formularies to include EUFLEXXA, hyaluronic sodium, as a co-preferred HA for osteoarthritis knee pain

November 18, 2019
·
3 min read
Job Trends

New Scientific Publication Shows Sera Prognostics Is Leader in Assessing Preterm Birth Risk

Highlights the Proper Experimental Design and Reporting Required for Accurate Biomarker Prediction Performance

November 18, 2019
·
4 min read
FDA

CooperCompanies Announces CooperVision Has Received FDA Approval of MiSight® for the Treatment of Myopia in ChildrenBecomes the First and Only FDA Approved Contact Lens of its Kind in the U.S.

CooperCompanies, announced that CooperVision has received U.S. Food and Drug Administration approval of its MiSight® 1 day contact lens1, indicated to slow the progression of myopia when initially prescribed for children 8-12 years old.

November 18, 2019
·
3 min read
Drug Development

Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study

Celldex Therapeutics, Inc. announced that a Phase 1a study of CDX-0159 has initiated in healthy volunteers.

November 18, 2019
·
6 min read
Drug Development

Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

Foamix Pharmaceuticals Ltd., a specialty pharmaceutical company, announced the completion of Phase 2 clinical trial enrollment of FCD105 for the treatment of moderate-to-severe acne vulgaris.

November 18, 2019
·
5 min read
BioMidwest

BioDuro chooses SciFinder-n from CAS to enhance research productivity and shorten cycle times for client success

Collaboration between drug companies and contract research partners drives innovation in evolving business environment

November 18, 2019
·
3 min read
Drug Development

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-301 in Patients with ASPH-Positive Head and Neck Cancer

Sensei Biotherapeutics, Inc. announced the dosing of the first patient in its Phase 1/2 clinical trial evaluating SNS-301 in patients with ASPH‑positive head and neck cancer who have previously received immune checkpoint inhibitors.

November 18, 2019
·
3 min read
Drug Development

Axial Biotherapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial Evaluating AB-2004 in Patients with Autism Spectrum Disorder

Axial Biotherapeutics announced the completion of enrollment in its Phase 1b/2a clinical trial evaluating AB-2004.

November 18, 2019
·
2 min read
FDA

Breakthrough CooperVision MiSight® 1 Day Contact Lens for Childhood Myopia Coming to the United States in 2020

FDA Approval Offers New Prospects for Parents, Children and Medical Professionals; Will Become the First and Only Product of its Kind Available in the U.S.

November 18, 2019
·
8 min read
Propanc Biopharma Advances POP1 Drug Discovery Program

Propanc Developing Backup Synthetic Compound to Lead Product Candidate, PRP

November 18, 2019
·
5 min read